Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study

被引:21
作者
Bongard, Vanina [1 ,2 ]
Dallongeville, Jean [3 ]
Arveiler, Dominique [4 ,5 ]
Ruidavets, Jean-Bernard [1 ,2 ]
Amouyel, Philippe [3 ]
Wagner, Aline [4 ]
Ferrieres, Jean [1 ,6 ]
机构
[1] Univ Toulouse 3, INSERM, UMR1027, Dept Epidemiol Econ Sante & Sante Publ, F-31062 Toulouse, France
[2] CHU Toulouse, Serv Epidemiol, Toulouse, France
[3] Univ Lille Nord France, INSERM, U744, Dept Epidemiol & Sante Publ,Inst Pasteur Lille, Lille, France
[4] Univ Strasbourg, Fac Med, EA 3430, Dept Epidemiol & Sante Publ, Strasbourg, France
[5] Hop Univ Strasbourg, Dept Sante Publ, Strasbourg, France
[6] CHU Toulouse, Hop Rangueil, Toulouse, France
关键词
Cardiovascular risk; Dyslipidaemia; Guidelines; LDL-cholesterol; Lipid-lowering therapy; TRENDS; DISEASE; PREVALENCE; FRANCE; EUROPE; ADULTS; LIPIDS;
D O I
10.1016/j.acvd.2012.11.003
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background. - Controlling low-density lipoprotein (LDL)-cholesterol concentration is of tremendous importance to reduce cardiovascular risk. Aims. - To investigate the attainment of LDL-cholesterol targets recommended in French and European guidelines on cardiovascular prevention, according to levels of cardiovascular risk. Methods. - Participants aged 35 to 74 years (n = 4609) were randomly selected from the general population of three French regions. A standardized data collection was performed to assess cardiovascular risk as described in the French and European guidelines. Results. - Overall, 17.5% of participants were considered to be at high risk and 25.4% at high or very high risk, according to the French and European guidelines, respectively. Only 1.2% of participants with no cardiovascular risk factors according to the French guidelines had an LDL-cholesterol concentration above the recommended target, whereas 82.5% of high-risk subjects did not attain their goal (70.8% among high-risk subjects receiving lipid-lowering therapy). Among untreated people, the median reduction in LDL-cholesterol needed to reach target ranged from 6.6% (lowest-risk groups) to 36.0% (highest-risk subjects). When risk was classified according to the European guidelines, the majority of participants did not reach the recommended LDL-cholesterol targets, irrespective of their level of risk or lipid-lowering therapy. Conclusion. - In a majority of primary prevention candidates with multiple risk factors and in most high-risk subjects, LDL-cholesterol targets recommended by French guidelines are not being achieved, either because of insufficient treatment or because subjects are not recognized as being at risk. More stringent targets proposed by the European guidelines are not being achieved in most cases. (c) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 22 条
[1]
Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use - The Minnesota Heart Survey, 1980-1982 to 2000-2002 [J].
Arnett, DK ;
Jacobs, DR ;
Luepker, RV ;
Blackburn, H ;
Armstrong, C ;
Claas, SA .
CIRCULATION, 2005, 112 (25) :3884-3891
[2]
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study [J].
Banegas, Jose R. ;
Lopez-Garcia, Esther ;
Dallongeville, Jean ;
Guallar, Eliseo ;
Halcox, Julian P. ;
Borghi, Claudio ;
Masso-Gonzalez, Elvira L. ;
Jimenez, Francisco J. ;
Perk, Joep ;
Gabriel Steg, Philippe ;
De Backer, Guy ;
Rodriguez-Artalejo, Fernando .
EUROPEAN HEART JOURNAL, 2011, 32 (17) :2143-2152
[3]
Trends in serum lipids and lipoproteins of adults, 1960-2002 [J].
Carroll, MD ;
Lacher, DA ;
Sorlie, PD ;
Cleeman, JI ;
Gordon, DJ ;
Wolz, M ;
Grundy, SM ;
Johnson, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14) :1773-1781
[4]
Centers for disease control prevention, 2012, TOT HIGH DENS LIP CH
[5]
Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project [J].
Conroy, RM ;
Pyörälä, K ;
Fitzgerald, AP ;
Sans, S ;
Menotti, A ;
De Backer, G ;
De Bacquer, D ;
Ducimetière, P ;
Jousilahti, P ;
Keil, U ;
Njolstad, I ;
Oganov, RG ;
Thomsen, T ;
Tunstall-Pedoe, H ;
Tverdal, A ;
Wedel, H ;
Whincup, P ;
Wilhelmsen, L ;
Graham, IM .
EUROPEAN HEART JOURNAL, 2003, 24 (11) :987-1003
[6]
Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study [J].
Dallongeville, Jean ;
Banegas, Jose R. ;
Tubach, Florence ;
Guallar, Eliseo ;
Borghi, Claudio ;
De Backer, Guy ;
Halcox, Julian P. J. ;
Masso-Gonzalez, Elvira L. ;
Perk, Joep ;
Sazova, Ogun ;
Steg, Philippe Gabriel ;
Rodriguez Artalejo, Fernando .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2012, 19 (03) :541-550
[7]
Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study [J].
Eliasson, M. ;
Janlert, U. ;
Jansson, J. -H. ;
Stegmayr, B. .
JOURNAL OF INTERNAL MEDICINE, 2006, 260 (06) :551-559
[8]
Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations?: The PRIME Study [J].
Empana, JP ;
Ducimetière, P ;
Arveiler, D ;
Ferrières, J ;
Evans, A ;
Ruidavets, JB ;
Haas, B ;
Yarnell, J ;
Bingham, A ;
Amouyel, P ;
Dallongeville, J .
EUROPEAN HEART JOURNAL, 2003, 24 (21) :1903-1911
[9]
Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007 [J].
Ferrieres, Jean ;
Bongard, Vanina ;
Dallongeville, Jean ;
Arveiler, Dominique ;
Cottel, Dominique ;
Haas, Bernadette ;
Wagner, Aline ;
Amouyel, Philippe ;
Ruidavets, Jean-Bernard .
ARCHIVES OF CARDIOVASCULAR DISEASES, 2009, 102 (04) :293-301
[10]
Assessment of lipid-lowering treatment in France - The CEPHEUS study [J].
Ferrieres, Jean ;
Gousse, Elisabeth Tocque-Le ;
Fabry, Caroline ;
Hermans, Michel P. .
ARCHIVES OF CARDIOVASCULAR DISEASES, 2008, 101 (09) :557-563